Study finds Lyme disease patients 4x more likely to have antibodies to other tick-borne pathogens.

A large study of over 193,000 U.S. patients found that nearly 30% of those with Lyme disease antibodies also had antibodies to other tick-borne pathogens like Babesia and Anaplasma. This co-exposure is especially common in the Northeast and highlights the need for comprehensive testing since symptoms overlap and treatment differs. The study underscores rising tick-borne illness risks due to environmental changes and calls for better diagnostic approaches to avoid missed infections and improve patient care.

Quest Diagnostics Inc (DGX) holds a market cap of $27.20 billion and offers a dividend yield of 1.4%, reflecting its established position in the health sector. As of September 21, 2026, 19:02 WIB, DGX shares are stable with no change in price, trading at USD 246.48 on Pluang. The study's findings on tick-borne diseases highlight the relevance of companies like Quest Diagnostics in advancing diagnostic testing technologies.